Ovarian malignant mixed mesodermal tumor response to cis-diamminedichloroplatinum.
A patient with primary, bulky, Stage III, malignant mixed mesodermal tumor (MMMT) of the ovary achieved a partial response to postoperative cis-Diamminedichloroplatinum (DDP). These rare tumors have previously been relatively resistant to chemotherapeutic agents. The use of DDP resulted in significant palliation in our patient and should be strongly considered in the postoperative therapy of patients with MMMT of the ovary.
Graciansky
A M
AM
Department of Obstetrics and Gynecology - Akron General Medical Center, Ohio.
Jenison
E L
EL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D000970:Antineoplastic Agents; D002945:Cisplatin; C043804:diamminedichlorodihydroxyplatinum IV